Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

RegulatoryapprovedGuardant360® CDxETCAMAH™Positive

AI Analysis

Summary

Guardant Health announced European approval of Guardant360® CDx as a companion diagnostic for AstraZeneca's camizestrant (ETCAMAH™) in advanced ER-positive breast cancer treatment.

Outcome Details

European approval of Guardant360® CDx as companion diagnostic for camizestrant

Importance:7/10

Sentiment:

0.80

companion diagnosticregulatory approvalEuropebreast cancerpartnership

Related Companies

$GH $AZN

Read the original article

Published by yahoo_finance on October 8, 2026 8:12 PM

Read Original